杭州天目山药业股份有限公司 章 程 （2025年 8月修订） （尚需提交2025 年第三次临时股东大会审议） 二〇二五年八月 目 录 杭州天目山药业股份有限公司章程 …………………………………………………… 第 1 页 第一章 总则 第一条 为维护公司、股东、职工和债权人的合法权益，规范公 司 的组 织和 行 为， 根 据《 中华 人 民共 和 国公 司法 》 （以 下 简称 "《公司法》"）《中华人民共和国证券法》（以下简称"《证券 法》"）、《上市公司章程指引》《上海证券交易所股票上市规则》 和其他有关规定，制定本章程。 第二条 公 司 1989 年 10 月 31 日 经 临 安 县 人 民 政 府 临 政 发 〔1989〕18 号文件批准，作为临安市首家国有企业股份制试点单位， 由杭州天目山药厂发起并认购部分股份和向社会公开募集股份而设 立股份制企业；1992 年根据国家体改委发布的《股份有限公司规范 意见》进行规范；1993 年又根据《公司法》进行了重新规范；公司 依法在浙江省市场监督管理局注册登记，取得营业执照，统一社会 信用代码：91330000253930812T。 第三条 公司于 1989 ...

陕西康惠制药股份有限公司（以下简称"公司"）于 2025 年 8 月 25 日取得 陕西省药品监督管理局换发的《药品生产许可证》 （许可证编号：陕 20160073）， 换发后的《药品生产许可证》有效期至 2030 年 8 月 24 日，具体情况如下： 一、《药品生产许可证》的主要信息 企业名称：陕西康惠制药股份有限公司 证券代码：603139 证券简称：康惠制药 公告编号：2025-052 陕西康惠制药股份有限公司 关于换发药品生产许可证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 生产负责人：郭建刚 许可证编号：陕 20160073 社会信用代码：916100006984144239 分类码：AhzCz 注册地址：陕西省咸阳市秦都区高新技术产业开发区彩虹二路 法定代表人：王延岭 企业负责人：王延岭 质量负责人：郝红梅 质量授权人：郝红梅 有效期至：2030 年 8 月 24 日 生产地址和生产范围： 陕西省咸阳市秦都区高新技术产业开发区胭脂路 36 号：膏药，软膏剂，茶 剂，颗粒剂，硬胶囊剂，片剂，酒剂，合剂，搽 ...

Core Viewpoint - The article discusses the results of drug production supervision inspections conducted by the Jiangxi Provincial Drug Supervision Administration from January to June 2025, highlighting compliance and non-compliance among various pharmaceutical companies [2][3][4]. Summary by Category Inspection Results - A total of 23 pharmaceutical companies were inspected during the first half of 2025, with most companies found to be compliant with the Good Manufacturing Practice (GMP) standards [2][3]. - Specific companies such as Jiangxi Ma Kang Pharmaceutical Co., Ltd. and Jiangxi Chengzhi Yongfeng Pharmaceutical Co., Ltd. were noted for their compliance in producing various drug forms including eye drops and traditional Chinese medicine [2][3]. Compliance Details - Companies like Jiangxi Qinfeng Pharmaceutical Co., Ltd. and Jiangxi Yichuan Pharmaceutical Technology Co., Ltd. were recognized for their adherence to GMP during inspections, covering a range of products from small volume injections to tablets [3][4]. - The inspections included checks on production lines for specific drugs, ensuring that companies met the required safety and quality standards [2][3]. Non-Compliance Issues - Some companies faced issues during inspections, although the article primarily focuses on those that complied with regulations [2][3]. - The inspections aimed to ensure that all pharmaceutical products manufactured in the province meet the necessary legal and quality standards [2][3][4].

Core Viewpoint - The Heilongjiang Provincial Drug Administration announced the results of the GMP compliance inspections for 16 pharmaceutical companies, confirming their adherence to the 2010 revised Good Manufacturing Practice standards [3]. Group 1: Compliance Inspection Results - Heilongjiang Sanlian Pharmaceutical Co., Ltd. was inspected for its small-volume injection production line, specifically for anti-tumor drugs, and found compliant [3]. - Harbin Pharmaceutical Group's second factory was inspected for its granule and oral liquid production lines, confirming compliance [3]. - Heilongjiang Huabei Pharmaceutical Co., Ltd. was inspected for its solid dosage forms and traditional Chinese medicine extraction processes, and was found compliant [3]. Group 2: Inspection Details - The inspections were conducted between April and May 2025, with specific dates for each company listed [3]. - The inspection covered various production lines, including small-volume injections, oral liquids, and traditional Chinese medicine extracts [3]. - The results indicate a focus on ensuring quality and compliance within the pharmaceutical manufacturing sector in Heilongjiang Province [3].

Core Points - The company is Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd, established in 1993 and registered in Jilin Province, China [4][6][7] - The company aims to build a health industry chain and ecosystem, contributing to the modernization and internationalization of the national health industry while maximizing shareholder returns [9] - The registered capital of the company is RMB 966,494,707 [7] Chapter Summaries Chapter 1: General Principles - The company is established to protect the rights of shareholders, employees, and creditors, following the Company Law and Securities Law of the People's Republic of China [4] - The company has undergone several changes in its registration and licensing, including a name change to Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd in 2000 [6][7] Chapter 2: Business Objectives and Scope - The business objectives include serving human health and contributing to the health industry [9] - The business scope includes manufacturing various pharmaceutical forms, research and development of traditional Chinese medicine, and medical project investments [9] Chapter 3: Shares - The company issues shares in the form of stocks, with a total of 966,494,707 shares issued, all being ordinary shares [10][21] - The company follows principles of fairness and transparency in share issuance [10] Chapter 4: Shareholders and Shareholder Meetings - Shareholders have rights to dividends, attend meetings, and supervise company operations [16] - The company must hold annual shareholder meetings within six months after the end of the fiscal year [25] Chapter 5: Board of Directors - The board of directors is responsible for the company's management and must act in the best interest of the company and its shareholders [18] - The company has provisions for independent directors and committees within the board [18] Chapter 6: Senior Management - Senior management includes the general manager, deputy general managers, and other key personnel [8] Chapter 7: Financial Accounting System, Profit Distribution, and Auditing - The company must adhere to a financial accounting system and undergo internal audits [8] Chapter 8: Notices and Announcements - The company is required to issue notices and announcements as per legal requirements [8] Chapter 9: Mergers, Divisions, Capital Increases, Reductions, Dissolution, and Liquidation - The company can merge, divide, increase or reduce capital, and dissolve according to legal procedures [8] Chapter 10: Amendments to the Articles - The company can amend its articles of association following the prescribed procedures [8] Chapter 11: Supplementary Provisions - The articles of association serve as a binding document for the company, shareholders, directors, and senior management [8]